Richard Weinshilboum, MD, has established a research program at the Mayo Clinic that uses genomic techniques, including genomewide association studies and whole genome DNA sequencing, which uses samples from large numbers of patients treated with a specific anticancer or antidepressant drug. He sat down with Federal Practitioner to discuss the role genetic testing plays in personalized medicine.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.
Individualized therapy: 1:11
Common genetic variations: 2:41
Using genomics for preemptive treatment: 6:06
Privacy concerns: 7:44
Cost effectiveness: 8:43
Applying genomics: 10:06